Analysts at Wedbush began coverage on shares of Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) in a research note issued on Thursday, Briefing.com reports. The brokerage set an “outperform” rating and a $11.00 price target on the stock. Wedbush’s price target points to a potential upside of 131.09% from the company’s current price. Separately, […]